SF3B3

Summary

SF3B3 (splicing factor 3b subunit 3, HGNC:10770) is a protein-coding gene on chromosome 16q22.1, encoding Splicing factor 3B subunit 3 (Q15393). Component of the 17S U2 SnRNP complex of the spliceosome, a large ribonucleoprotein complex that removes introns from transcribed pre-mRNAs. It is a common-essential gene (DepMap: required in 99.9% of cancer cell lines).

This gene encodes subunit 3 of the splicing factor 3b protein complex. Splicing factor 3b, together with splicing factor 3a and a 12S RNA unit, forms the U2 small nuclear ribonucleoproteins complex (U2 snRNP). The splicing factor 3b/3a complex binds pre-mRNA upstream of the intron’s branch site in a sequence independent manner and may anchor the U2 snRNP to the pre-mRNA. Splicing factor 3b is also a component of the minor U12-type spliceosome. Subunit 3 has also been identified as a component of the STAGA (SPT3-TAF(II)31-GCN5L acetylase) transcription coactivator-HAT (histone acetyltransferase) complex, and the TFTC (TATA-binding-protein-free TAF(II)-containing complex). These complexes may function in chromatin modification, transcription, splicing, and DNA repair.

Source: NCBI Gene 23450 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 238 total — 1 likely-pathogenic
• Druggable target: yes — 3 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 99.9% of screened cell lines (common-essential)
• MANE Select transcript: NM_012426

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10770
Approved symbol	SF3B3
Name	splicing factor 3b subunit 3
Location	16q22.1
Locus type	gene with protein product
Status	Approved
Aliases	SAP130, SF3b130, RSE1, KIAA0017
Ensembl gene	ENSG00000189091
Ensembl biotype	protein_coding
OMIM	605592
Entrez	23450

Gene structure

Transcript identifiers

Ensembl transcripts: 38 — 29 protein_coding, 7 retained_intron, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000302516, ENST00000562722, ENST00000562874, ENST00000563739, ENST00000564899, ENST00000565990, ENST00000566095, ENST00000567250, ENST00000567635, ENST00000567654, ENST00000568291, ENST00000568539, ENST00000569687, ENST00000572365, ENST00000577085, ENST00000909657, ENST00000909658, ENST00000909659, ENST00000909660, ENST00000909661, ENST00000909662, ENST00000909663, ENST00000909664, ENST00000909665, ENST00000909666, ENST00000918229, ENST00000918230, ENST00000918231, ENST00000918232, ENST00000918233, ENST00000918234, ENST00000918235, ENST00000918236, ENST00000918237, ENST00000918238, ENST00000950010, ENST00000950011, ENST00000950012

RefSeq mRNA: 1 — MANE Select: NM_012426 NM_012426

CCDS: CCDS10894

Canonical transcript exons

ENST00000302516 — 26 exons

Exon	Start	End
ENSE00001201829	70570006	70570149
ENSE00001201835	70569043	70569141
ENSE00001201840	70568283	70568495
ENSE00001201844	70567411	70567536
ENSE00001201865	70560469	70560591
ENSE00001298396	70526587	70526726
ENSE00001318529	70528873	70529199
ENSE00001326124	70532479	70532620
ENSE00001328025	70530745	70530917
ENSE00001340034	70571673	70577668
ENSE00001404916	70538323	70538460
ENSE00001423663	70548370	70548442
ENSE00001425551	70535308	70535420
ENSE00001516024	70523816	70523928
ENSE00003499029	70539104	70539207
ENSE00003511147	70554446	70554597
ENSE00003524970	70556886	70557029
ENSE00003600445	70541669	70541834
ENSE00003602070	70561630	70561784
ENSE00003613307	70565368	70565524
ENSE00003613796	70565065	70565270
ENSE00003632238	70555051	70555206
ENSE00003643932	70563876	70564050
ENSE00003644595	70571095	70571199
ENSE00003649971	70556179	70556334
ENSE00003673507	70544438	70544533

Expression profiles

Bgee: expression breadth ubiquitous, 296 present calls, max score 99.43.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 124.1998 / max 1154.9011, expressed in 1821 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
154879	123.3904	1821
154888	0.5513	303
154878	0.1394	52
154884	0.0860	22
207934	0.0328	16

Top tissues by expression

300 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	99.43	gold quality
ganglionic eminence	UBERON:0004023	99.11	gold quality
cortical plate	UBERON:0005343	98.86	gold quality
stromal cell of endometrium	CL:0002255	98.43	gold quality
left ovary	UBERON:0002119	98.33	gold quality
adrenal tissue	UBERON:0018303	98.33	gold quality
right ovary	UBERON:0002118	98.31	gold quality
ectocervix	UBERON:0012249	98.30	gold quality
skin of leg	UBERON:0001511	98.21	gold quality
skin of abdomen	UBERON:0001416	98.19	gold quality
lower esophagus mucosa	UBERON:0035834	98.17	gold quality
esophagus mucosa	UBERON:0002469	98.08	gold quality
endocervix	UBERON:0000458	98.05	gold quality
body of uterus	UBERON:0009853	98.00	gold quality
colonic epithelium	UBERON:0000397	97.87	gold quality
right lobe of thyroid gland	UBERON:0001119	97.87	gold quality
embryo	UBERON:0000922	97.75	gold quality
right uterine tube	UBERON:0001302	97.69	gold quality
peripheral nervous system	UBERON:0000010	97.60	gold quality
tibial nerve	UBERON:0001323	97.60	gold quality
esophagus	UBERON:0001043	97.51	gold quality
minor salivary gland	UBERON:0001830	97.51	gold quality
left lobe of thyroid gland	UBERON:0001120	97.50	gold quality
left uterine tube	UBERON:0001303	97.48	gold quality
islet of Langerhans	UBERON:0000006	97.45	gold quality
adenohypophysis	UBERON:0002196	97.39	gold quality
body of pancreas	UBERON:0001150	97.31	gold quality
granulocyte	CL:0000094	97.20	gold quality
mouth mucosa	UBERON:0003729	97.10	gold quality
thyroid gland	UBERON:0002046	96.99	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	11.27
E-MTAB-6678	no	3.13

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

191 targeting SF3B3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-4645-5P	99.98	65.81	1284
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-548AJ-3P	99.96	73.38	5345

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 99.9% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 7)

• our findings suggest a role for the elevated expression of SF3B3 in poor prognosis and tamoxifen resistance, leading to recurrence of estrogen receptor-positive breast cancer (PMID:25431237)
• Report detection of SF3B3 gene mutations in oral cancer using high resolution melting analysis. (PMID:25651737)
• These results suggest SF3B3 as a key regulator of EZH2 pre-mRNA splicing and SF3B3 may represent a novel prognostic factor and potential therapeutic target in clear cell renal cell carcinoma (PMID:27879367)
• SAP130 is a potential noninvasive biomarker that correlates well with Crohn’s disease severity. (PMID:31583714)
• Ambiguity about Splicing Factor 3b Subunit 3 (SF3B3) and Sin3A Associated Protein 130 (SAP130). (PMID:33800128)
• LINC01348 suppresses hepatocellular carcinoma metastasis through inhibition of SF3B3-mediated EZH2 pre-mRNA splicing. (PMID:34140643)
• SF3B3-regulated mTOR alternative splicing promotes colorectal cancer progression and metastasis. (PMID:38671459)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	sf3b3	ENSDARG00000103553
mus_musculus	Sf3b3	ENSMUSG00000033732
rattus_norvegicus	Sf3b3	ENSRNOG00000017724
drosophila_melanogaster	Sf3b3	FBGN0035162
caenorhabditis_elegans	teg-4	WBGENE00019323

Paralogs (2): CPSF1 (ENSG00000071894), DDB1 (ENSG00000167986)

Protein

Protein identifiers

Splicing factor 3B subunit 3 — Q15393 (reviewed: Q15393)

Alternative names: Pre-mRNA-splicing factor SF3b 130 kDa subunit, STAF130, Spliceosome-associated protein 130

All UniProt accessions (6): Q15393, H3BMB0, I3L4G7, J3QKV4, J3QL37, J3QRB2

UniProt curated annotations — full annotation on UniProt →

Function. Component of the 17S U2 SnRNP complex of the spliceosome, a large ribonucleoprotein complex that removes introns from transcribed pre-mRNAs. The 17S U2 SnRNP complex (1) directly participates in early spliceosome assembly and (2) mediates recognition of the intron branch site during pre-mRNA splicing by promoting the selection of the pre-mRNA branch-site adenosine, the nucleophile for the first step of splicing. Within the 17S U2 SnRNP complex, SF3B3 is part of the SF3B subcomplex, which is required for ‘A’ complex assembly formed by the stable binding of U2 snRNP to the branchpoint sequence in pre-mRNA. Sequence independent binding of SF3A and SF3B subcomplexes upstream of the branch site is essential, it may anchor U2 snRNP to the pre-mRNA. May also be involved in the assembly of the ‘E’ complex. Also acts as a component of the minor spliceosome, which is involved in the splicing of U12-type introns in pre-mRNAs.

Subunit / interactions. Component of the 17S U2 SnRNP complex, a ribonucleoprotein complex that contains small nuclear RNA (snRNA) U2 and a number of specific proteins. Part of the SF3B subcomplex of the 17S U2 SnRNP complex. SF3B associates with the splicing subcomplex SF3A and a 12S RNA unit to form the U2 small nuclear ribonucleoproteins complex (U2 snRNP). Within the SF3B subcomplex, interacts directly with SF3B1 (via HEAT domain), SF3B5 and PHF5A. Identified in the spliceosome A complex; remains associated with the spliceosome throughout the splicing process. Component of the spliceosome B complex. Identified in the spliceosome C complex. Identified in the spliceosome E complex. Component of the minor (U12-type spliceosome) spliceosome. Within this complex, interacts with SCNM1. Associates with the STAGA transcription coactivator-HAT complex. Interacts with SUPT3H. Interacts with TAF3.

Subcellular location. Nucleus.

Domain organisation. The core of the protein consists of three beta-propeller domains.

Similarity. Belongs to the RSE1 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q15393-1	1	yes
Q15393-2	2
Q15393-3	3

RefSeq proteins (1): NP_036558* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004871	RSE1/DDB1/CPSF1_C	Domain
IPR015943	WD40/YVTN_repeat-like_dom_sf	Homologous_superfamily
IPR018846	Beta-prop_RSE1/DDB1/CPSF1_1st	Domain
IPR036322	WD40_repeat_dom_sf	Homologous_superfamily
IPR050358	RSE1/DDB1/CFT1	Family
IPR058543	Beta-prop_RSE1/DDB1/CPSF1_2nd	Domain

Pfam: PF03178, PF10433, PF23726

UniProt features (168 total): strand 118, turn 13, helix 13, site 7, region of interest 6, sequence conflict 4, splice variant 3, modified residue 2, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

67 structures, top 30 by resolution.

PDB	Method	Resolution (Å)
7Q4O	ELECTRON MICROSCOPY	2.1
7Q4P	ELECTRON MICROSCOPY	2.15
7Q3L	ELECTRON MICROSCOPY	2.21
7B9C	X-RAY DIFFRACTION	2.4
9RDK	ELECTRON MICROSCOPY	2.41
7EVO	ELECTRON MICROSCOPY	2.5
7EVN	ELECTRON MICROSCOPY	2.6
8H6L	ELECTRON MICROSCOPY	2.6
8H6K	ELECTRON MICROSCOPY	2.7
8HK1	ELECTRON MICROSCOPY	2.7
7DVQ	ELECTRON MICROSCOPY	2.89
7B0I	X-RAY DIFFRACTION	3
7B91	X-RAY DIFFRACTION	3
7B92	X-RAY DIFFRACTION	3
7OMF	X-RAY DIFFRACTION	3
7VPX	ELECTRON MICROSCOPY	3
8I0R	ELECTRON MICROSCOPY	3
8I0T	ELECTRON MICROSCOPY	3
8I0V	ELECTRON MICROSCOPY	3
6EN4	X-RAY DIFFRACTION	3.08
5IFE	X-RAY DIFFRACTION	3.1
7ONB	ELECTRON MICROSCOPY	3.1
7OPI	X-RAY DIFFRACTION	3.1
7QTT	ELECTRON MICROSCOPY	3.1
9K1Y	ELECTRON MICROSCOPY	3.1
8H6E	ELECTRON MICROSCOPY	3.2
8H6J	ELECTRON MICROSCOPY	3.25
9ZE2	ELECTRON MICROSCOPY	3.26
6QX9	ELECTRON MICROSCOPY	3.28
8I0U	ELECTRON MICROSCOPY	3.3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q15393-F1	92.36	0.79

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (7): 429 (interaction with sf3b5); 916 (interaction with sf3b5); 988 (interaction with sf3b1); 1171 (interaction with sf3b1); 284 (interaction with sf3b5); 306 (interaction with sf3b5); 352 (interaction with sf3b5)

Post-translational modifications (2): 156, 1200

Function

Pathways and Gene Ontology

Reactome pathways

8 pathways

ID	Pathway
R-HSA-72163	mRNA Splicing - Major Pathway
R-HSA-72165	mRNA Splicing - Minor Pathway
R-HSA-9770562	mRNA Polyadenylation
R-HSA-9918481	Dengue Virus-Host Interactions
R-HSA-9943411	CHD1 and CHD2 subfamily
R-HSA-72172	mRNA Splicing
R-HSA-72203	Processing of Capped Intron-Containing Pre-mRNA
R-HSA-8953854	Metabolism of RNA

MSigDB gene sets: 327 (showing top): GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_DN, GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_UP, GSE45365_NK_CELL_VS_CD8A_DC_UP, GSE45365_NK_CELL_VS_BCELL_UP, RNGTGGGC_UNKNOWN, GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, chr16q22, PAX4_01, NAGY_STAGA_COMPONENTS_HUMAN, KANG_FLUOROURACIL_RESISTANCE_UP, GCM_GSPT1, BOYAULT_LIVER_CANCER_SUBCLASS_G2, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, DITTMER_PTHLH_TARGETS_UP, GOBP_MACROMOLECULE_CATABOLIC_PROCESS

GO Biological Process (9): RNA splicing, via transesterification reactions (GO:0000375), mRNA splicing, via spliceosome (GO:0000398), regulation of DNA repair (GO:0006282), RNA splicing (GO:0008380), negative regulation of protein catabolic process (GO:0042177), regulation of RNA splicing (GO:0043484), positive regulation of DNA-templated transcription (GO:0045893), U2-type prespliceosome assembly (GO:1903241), mRNA processing (GO:0006397)

GO Molecular Function (4): U2 snRNA binding (GO:0030620), protein-containing complex binding (GO:0044877), nucleic acid binding (GO:0003676), protein binding (GO:0005515)

GO Cellular Component (10): SAGA complex (GO:0000124), nucleus (GO:0005634), nucleoplasm (GO:0005654), spliceosomal complex (GO:0005681), U2-type spliceosomal complex (GO:0005684), U2 snRNP (GO:0005686), U12-type spliceosomal complex (GO:0005689), nucleolus (GO:0005730), U2-type precatalytic spliceosome (GO:0071005), catalytic step 2 spliceosome (GO:0071013)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
mRNA Splicing	2
mRNA 3’-end processing	1
Dengue Virus Infection	1
CHD chromatin remodelers	1
Processing of Capped Intron-Containing Pre-mRNA	1
Metabolism of RNA	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	3
spliceosomal complex	3
RNA splicing	2
RNA processing	2
nuclear lumen	2
RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	1
mRNA processing	1
DNA repair	1
regulation of DNA metabolic process	1
regulation of cellular response to stress	1
negative regulation of catabolic process	1
protein catabolic process	1
regulation of protein catabolic process	1
negative regulation of protein metabolic process	1
regulation of gene expression	1
regulation of primary metabolic process	1
DNA-templated transcription	1
regulation of DNA-templated transcription	1
positive regulation of RNA biosynthetic process	1
spliceosomal complex assembly	1
mRNA metabolic process	1
snRNA binding	1
SAGA-type complex	1
DUBm complex	1
peptidase complex	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1
nuclear protein-containing complex	1
ribonucleoprotein complex	1
spliceosomal snRNP complex	1
intracellular membraneless organelle	1
U2-type spliceosomal complex	1
U1 snRNP	1
U2 snRNP	1
U4/U6 x U5 tri-snRNP complex	1
precatalytic spliceosome	1
Prp19 complex	1
U5 snRNP	1
catalytic complex	1

Protein interactions and networks

STRING

3307 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SF3B3	SF3B2	Q13435	999
SF3B3	SF3B5	Q9BWJ5	997
SF3B3	PHF5A	Q7RTV0	996
SF3B3	SF3B4	Q15427	995
SF3B3	SF3B1	O75533	994
SF3B3	SF3B6	Q9Y3B4	990
SF3B3	SF3A3	Q12874	969
SF3B3	CLEC4E	Q9ULY5	947
SF3B3	HNRNPK	P61978	935
SF3B3	PUF60	Q9UHX1	910
SF3B3	SF3A2	Q15428	896
SF3B3	FXR2	P51116	895
SF3B3	SF3A1	Q15459	877
SF3B3	SNRPA1	P09661	847
SF3B3	EFTUD2	Q15029	844

IntAct

270 interactions, top by confidence:

A	B	Type	Score
PLK1	SPAG9	psi-mi:“MI:0914”(association)	0.790
SNRPE	GEMIN2	psi-mi:“MI:0914”(association)	0.770
TRRAP	ATXN7	psi-mi:“MI:0914”(association)	0.740
CCDC97	SF3B1	psi-mi:“MI:0914”(association)	0.730
PHF5A	SF3B1	psi-mi:“MI:0914”(association)	0.730
TUBA1C	TXNDC9	psi-mi:“MI:0914”(association)	0.730
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
SNRPD2	GEMIN2	psi-mi:“MI:0914”(association)	0.710
SNRPB	PRMT5	psi-mi:“MI:0914”(association)	0.670
SNRPA1	HTATSF1	psi-mi:“MI:0914”(association)	0.640
NCBP1	KPNA3	psi-mi:“MI:0914”(association)	0.640
NCBP2	KPNA3	psi-mi:“MI:0914”(association)	0.640
DNAJC8	SF3B1	psi-mi:“MI:0914”(association)	0.640
SF3B1	SAP18	psi-mi:“MI:0914”(association)	0.640
SNRPA1	U2SURP	psi-mi:“MI:0914”(association)	0.640
SF3B4	SF3B1	psi-mi:“MI:0914”(association)	0.610
PPP4R2	SF3B1	psi-mi:“MI:0914”(association)	0.570
PPP4R2	SF3B1	psi-mi:“MI:2364”(proximity)	0.570
CHEK2	PPM1G	psi-mi:“MI:0914”(association)	0.560
SF3B3	SF3A3	psi-mi:“MI:0915”(physical association)	0.560
CASP6	SF3B3	psi-mi:“MI:0915”(physical association)	0.560
HIP1	SF3B3	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (774): SF3B3 (Affinity Capture-MS), SF3B3 (Affinity Capture-MS), SF3B3 (Affinity Capture-RNA), SF3B3 (Affinity Capture-MS), SF3B3 (Affinity Capture-MS), SF3B3 (Affinity Capture-MS), SF3B3 (Affinity Capture-MS), SF3B3 (Affinity Capture-MS), SF3B3 (Affinity Capture-MS), SF3B3 (Affinity Capture-MS), SF3B3 (Affinity Capture-MS), SF3B3 (Affinity Capture-MS), SF3B3 (Affinity Capture-MS), SF3B3 (Affinity Capture-RNA), BCAS2 (Co-fractionation)

ESM2 similar proteins: A0JN52, A1A4K3, A8XPU7, O49552, P0CR22, P0CR23, P0DKL4, P0DKL6, P33194, Q15393, Q16531, Q1LVE8, Q21554, Q3SYG4, Q3U1J4, Q3V3N7, Q4ADV7, Q4PGM6, Q4WLI5, Q52E49, Q54SA7, Q5B1X8, Q5BDG7, Q5DM57, Q5R649, Q5RBI5, Q69ZJ7, Q6AX60, Q6CAH5, Q6E7D1, Q6L4S0, Q6P6Z0, Q6QNU4, Q753D4, Q7RYR4, Q7XWP1, Q805F9, Q811G0, Q8NFJ9, Q921M3

Diamond homologs: A0JN52, P0CR22, P0CR23, P0DKL4, P0DKL6, Q15393, Q1LVE8, Q4PGM6, Q4WLI5, Q52E49, Q54SA7, Q5A7S5, Q5B1X8, Q5RBI5, Q6BYK1, Q7RYR4, Q921M3, Q9UTT2, Q9W0M7, Q6CAH5, Q7XWP1

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
SF3B3	“form complex”	SF3b	binding
SF3B3	“form complex”	“U2 snRNP complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 194 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Metabolism of non-coding RNA	7	30.4×	1e-07
mRNA Splicing	27	20.3×	3e-26
mRNA Polyadenylation	31	18.6×	8e-29
Processing of Capped Intron-Containing Pre-mRNA	30	16.9×	1e-26
mRNA Splicing - Minor Pathway	11	16.9×	3e-09
mRNA Splicing - Major Pathway	42	15.7×	2e-36
CHD1 and CHD2 subfamily	21	15.6×	1e-17
snRNP Assembly	8	11.6×	2e-05

GO biological processes:

GO term	Partners	Fold	FDR
U2-type prespliceosome assembly	16	55.5×	1e-22
spliceosomal complex assembly	9	30.1×	3e-09
mRNA cis splicing, via spliceosome	5	27.5×	8e-05
spliceosomal snRNP assembly	8	25.8×	1e-07
RNA splicing, via transesterification reactions	7	24.3×	1e-06
amyloid fibril formation	6	20.1×	5e-05
mRNA splicing, via spliceosome	37	18.8×	8e-34
RNA processing	10	12.2×	1e-06

Disease & clinical

Clinical variants and AI predictions

ClinVar

238 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	177
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
808800	NM_001330301.2(SAP130):c.181C>T (p.Gln61Ter)	Likely pathogenic

SpliceAI

7009 predictions. Top by Δscore:

Variant	Effect	Δscore
16:70526583:TTAGC:T	acceptor_loss	1.0000
16:70526585:A:AG	acceptor_gain	1.0000
16:70526585:AGC:A	acceptor_loss	1.0000
16:70526586:G:GG	acceptor_gain	1.0000
16:70526586:GC:G	acceptor_gain	1.0000
16:70526586:GCT:G	acceptor_gain	1.0000
16:70526586:GCTT:G	acceptor_gain	1.0000
16:70526586:GCTTT:G	acceptor_gain	1.0000
16:70526724:CTGGT:C	donor_loss	1.0000
16:70526725:TGG:T	donor_loss	1.0000
16:70526726:GGTA:G	donor_loss	1.0000
16:70526727:G:GG	donor_gain	1.0000
16:70526727:GTAAG:G	donor_loss	1.0000
16:70526728:TAA:T	donor_loss	1.0000
16:70527430:G:GG	donor_gain	1.0000
16:70528869:CTA:C	acceptor_loss	1.0000
16:70528870:TA:T	acceptor_loss	1.0000
16:70528871:A:AT	acceptor_loss	1.0000
16:70529195:GATTA:G	donor_gain	1.0000
16:70529196:ATTA:A	donor_gain	1.0000
16:70529197:TTA:T	donor_gain	1.0000
16:70529198:TA:T	donor_gain	1.0000
16:70529199:AGTA:A	donor_loss	1.0000
16:70529200:G:GG	donor_gain	1.0000
16:70529201:T:A	donor_loss	1.0000
16:70532476:TA:T	acceptor_loss	1.0000
16:70532616:TACAG:T	donor_loss	1.0000
16:70532617:ACAG:A	donor_loss	1.0000
16:70532618:CAG:C	donor_loss	1.0000
16:70532619:AG:A	donor_loss	1.0000

AlphaMissense

7948 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:70526715:G:A	G20E	1.000
16:70529046:A:C	S82R	1.000
16:70529048:T:A	S82R	1.000
16:70529048:T:G	S82R	1.000
16:70529056:G:A	G85D	1.000
16:70529059:G:C	R86P	1.000
16:70529125:G:A	G108D	1.000
16:70529181:G:A	G127R	1.000
16:70529181:G:C	G127R	1.000
16:70529181:G:T	G127W	1.000
16:70529182:G:A	G127E	1.000
16:70529185:G:C	R128P	1.000
16:70529187:G:C	A129P	1.000
16:70529188:C:A	A129D	1.000
16:70530771:T:G	Y142D	1.000
16:70530782:C:A	N145K	1.000
16:70530782:C:G	N145K	1.000
16:70530784:G:C	R146T	1.000
16:70530784:G:T	R146I	1.000
16:70530785:A:C	R146S	1.000
16:70530785:A:T	R146S	1.000
16:70530817:C:A	P157H	1.000
16:70530820:T:C	L158P	1.000
16:70530826:C:A	A160D	1.000
16:70530876:T:C	F177L	1.000
16:70530878:T:A	F177L	1.000
16:70530878:T:G	F177L	1.000
16:70530884:T:A	N179K	1.000
16:70530884:T:G	N179K	1.000
16:70530886:C:A	P180Q	1.000

dbSNP variants (sampled 300 via entrez): RS1000072097 (16:70547742 G>A), RS1000085283 (16:70554390 G>A), RS1000144400 (16:70537207 G>A), RS1000179042 (16:70553997 A>C), RS1000222189 (16:70570089 A>T), RS1000337217 (16:70548240 G>A), RS1000421760 (16:70548066 G>T), RS1000456994 (16:70567215 G>A,C), RS1000683435 (16:70561391 G>C,T), RS1000747948 (16:70561270 C>T), RS1000766648 (16:70537968 A>G), RS1000819809 (16:70526503 C>T), RS1000856438 (16:70527281 G>A,T), RS1000857142 (16:70533212 G>A), RS1000864515 (16:70544037 A>G)

Disease associations

OMIM: gene MIM:605592 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST005025_5	Anti-saccade response	8.000000e-07
GCST006993_12	Hippocampal volume in Alzheimer’s disease dementia	1.000000e-07
GCST010396_160	Gut microbiota (bacterial taxa, hurdle binary method)	2.000000e-06
GCST010703_100	Brain morphology (MOSTest)	2.000000e-40
GCST010725_47	Malaria	6.000000e-07

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0006874	antisaccade response measurement
EFO:0005035	hippocampal volume
EFO:0007874	gut microbiome measurement
EFO:0004346	neuroimaging measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL1250378 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

3 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 119,020 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL269732	TACROLIMUS ANHYDROUS	4	95,168
CHEMBL1232461	MOLIBRESIB	2	1,538
CHEMBL99	TRICHOSTATIN	1	22,314

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

6 measured of 6 human assays (6 total across all organisms); most potent 6 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
(3R,6R,7S,8E,10S,11S,12E,14E,16S,18R,19R,20R,21S)-7-acetoxy-3,6,21-trihydroxy-6,10,12,16,20-pentamethyl-18,19-epoxytricosa-8,12,14-triene-11-olide	EC50	0.86 nM
(3R,6R,7S,8E,10S,11S,12E,14E,16R,18R,19R,20R,21S)-7-[(4-cycloheptylpiperazin-1-yl)carbonyl]oxy-3,6,16,21-tetrahydroxy-6,10,12,16,20-pentamethyl-18,19-epoyxtrichosa-8,12,14-trien-11-olide	EC50	3.2 nM
(3R,6R,7S,8E,10S,11S,12E,14E,16R,18R,19R,20R,21S)-7-acetoxy-3,6,16,21-tetrahydroxy-6,10,12,16,20-pentamethyl-18,19-epoxytricosa-8,12,14-triene-11-olide	EC50	4.3 nM
CID16202133	EC50	4.9 nM
CID1620213	EC50	595 nM
CID16202134	EC50	645 nM

ChEMBL bioactivities

26 potent at pChembl≥5 of 28 total, top 26 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.00	IC50	1	nM	PLADIENOLIDE B
8.89	IC50	1.3	nM	PLADIENOLIDE B
8.49	IC50	3.2	nM	CHEMBL1240972
8.48	IC50	3.3	nM	PLA D
8.44	IC50	3.6	nM	CHEMBL1240972
8.37	IC50	4.3	nM	PLA D
8.31	IC50	4.9	nM	CHEMBL1242284
8.30	IC50	5	nM	PLADIENOLIDE C
8.18	IC50	6.6	nM	CHEMBL1242284
8.13	IC50	7.4	nM	PLADIENOLIDE C
7.96	IC50	10.9	nM	TACROLIMUS ANHYDROUS
7.86	IC50	13.8	nM	TACROLIMUS ANHYDROUS
7.23	IC50	58.9	nM	PLADIENOLIDE E
7.19	IC50	65.2	nM	PLADIENOLIDE E
7.11	IC50	78.4	nM	CHEMBL1240973
6.51	IC50	307.7	nM	PLADIENOLIDE A
6.38	IC50	418.1	nM	PLADIENOLIDE A
6.24	IC50	577.6	nM	TRICHOSTATIN
6.21	IC50	611.2	nM	TRICHOSTATIN
6.19	IC50	644.8	nM	CHEMBL1240974
5.67	IC50	2154	nM	PLADIENOLIDE F
5.54	IC50	2894	nM	PLADIENOLIDE F
5.46	IC50	3481	nM	LACTACYSTIN
5.22	Kd	6084	nM	CHEMBL5653589
5.22	ED50	6084	nM	CHEMBL5653589
5.11	Kd	7753	nM	MOLIBRESIB

PubChem BioAssay actives

37 with measured affinity, of 102 total; 21 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
[(2S,3S,4E,6S,7R,10R)-7,10-dihydroxy-2-[(2E,4E,6S)-7-[(2R,3R)-3-[(2R,3S)-3-hydroxypentan-2-yl]oxiran-2-yl]-6-methylhepta-2,4-dien-2-yl]-3,7-dimethyl-12-oxo-1-oxacyclododec-4-en-6-yl] acetate	1799385: WiDr from Article 10.1038/nchembio.2007.16: “Splicing factor SF3b as a target of the antitumor natural product pladienolide.”	ec50	0.0009	uM
[(2S,3S,6S,7R,10R)-7,10-dihydroxy-2-[(2E,4E,6S)-7-[(2R,3R)-3-[(2R,3S)-3-hydroxypentan-2-yl]oxiran-2-yl]-6-methylhepta-2,4-dien-2-yl]-3,7-dimethyl-12-oxo-oxacyclododec-6-yl] acetate	506784: Inhibition of SAP130 mediated cell growth in human WiDr cells	ic50	0.0010	uM
[(2S,3S,4E,6S,7R,10R)-7,10-dihydroxy-2-[(2E,4E,6R)-6-hydroxy-7-[(2R,3R)-3-[(2R,3S)-3-hydroxypentan-2-yl]oxiran-2-yl]-6-methylhepta-2,4-dien-2-yl]-3,7-dimethyl-12-oxo-1-oxacyclododec-4-en-6-yl] 4-cycloheptylpiperazine-1-carboxylate	1799385: WiDr from Article 10.1038/nchembio.2007.16: “Splicing factor SF3b as a target of the antitumor natural product pladienolide.”	ec50	0.0032	uM
[(2S,3S,6S,7R,10R)-7,10-dihydroxy-2-[(2E,4E,6R)-6-hydroxy-7-[(2R,3R)-3-[(2R,3S)-3-hydroxypentan-2-yl]oxiran-2-yl]-6-methylhepta-2,4-dien-2-yl]-3,7-dimethyl-12-oxo-oxacyclododec-6-yl] 4-cycloheptylpiperazine-1-carboxylate	506784: Inhibition of SAP130 mediated cell growth in human WiDr cells	ic50	0.0032	uM
[(2S,3S,6S,7R,10R)-7,10-dihydroxy-2-[(2E,4E,6R)-6-hydroxy-7-[(2R,3R)-3-[(2R,3S)-3-hydroxypentan-2-yl]oxiran-2-yl]-6-methylhepta-2,4-dien-2-yl]-3,7-dimethyl-12-oxo-oxacyclododec-6-yl] acetate	507021: Inhibition of SAP130 in VEGF-stimulated human U251 cells by PLAP reporter gene assay	ic50	0.0033	uM
[(2S,3S,4E,6S,7R,10R)-7,10-dihydroxy-2-[(2E,4E,6R)-6-hydroxy-7-[(2R,3R)-3-[(2R,3S)-3-hydroxypentan-2-yl]oxiran-2-yl]-6-methylhepta-2,4-dien-2-yl]-3,7-dimethyl-12-oxo-1-oxacyclododec-4-en-6-yl] acetate	1799384: VEGF-PLAP from Article 10.1038/nchembio.2007.16: “Splicing factor SF3b as a target of the antitumor natural product pladienolide.”	ec50	0.0043	uM
[(2S,3S,4E,6S,7R,10R)-7,10-dihydroxy-2-[(2E,4E,6S)-7-[(2R,3R)-3-[(2R,3S)-3-hydroxypentan-2-yl]oxiran-2-yl]-6-methylhepta-2,4-dien-2-yl]-3,7-dimethyl-12-oxo-1-oxacyclododec-4-en-6-yl] N-ethylcarbamate	1799384: VEGF-PLAP from Article 10.1038/nchembio.2007.16: “Splicing factor SF3b as a target of the antitumor natural product pladienolide.”	ec50	0.0049	uM
[(2S,3S,6S,7R,10R)-7,10-dihydroxy-2-[(2E,4E,6S)-7-[(2R,3R)-3-[(2R,3S)-3-hydroxypentan-2-yl]oxiran-2-yl]-6-methylhepta-2,4-dien-2-yl]-3,7-dimethyl-12-oxo-oxacyclododec-6-yl] N-ethylcarbamate	506784: Inhibition of SAP130 mediated cell growth in human WiDr cells	ic50	0.0049	uM
[(2S,3S,6S,7R,10R)-7,10-dihydroxy-3,7-dimethyl-2-[(2E,4E,6S)-6-methyl-7-[(2R,3R)-3-[(2S)-3-oxopentan-2-yl]oxiran-2-yl]hepta-2,4-dien-2-yl]-12-oxo-oxacyclododec-6-yl] acetate	507021: Inhibition of SAP130 in VEGF-stimulated human U251 cells by PLAP reporter gene assay	ic50	0.0050	uM
Tacrolimus	506784: Inhibition of SAP130 mediated cell growth in human WiDr cells	ic50	0.0109	uM
[(2S,3S,6S,7R,10R)-2-[(2E,4E,6S)-7-[(2R,3S)-3-[(2S,3S)-2,3-dihydroxypentan-2-yl]oxiran-2-yl]-6-methylhepta-2,4-dien-2-yl]-7,10-dihydroxy-3,7-dimethyl-12-oxo-oxacyclododec-6-yl] acetate	507021: Inhibition of SAP130 in VEGF-stimulated human U251 cells by PLAP reporter gene assay	ic50	0.0589	uM
[(2S,3S,4E,6S,7R,10R)-7,10-dihydroxy-2-[(2E,4E,6S)-7-[(2R,3R)-3-[(2R,3S)-3-hydroxypentan-2-yl]oxiran-2-yl]-6-methylhepta-2,4-dien-2-yl]-3,7-dimethyl-12-oxo-1-oxacyclododec-4-en-6-yl] N-[2-[2-[2-[5-(2,2-difluoro-10,12-dimethyl-1-aza-3-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-3,5,7,9,11-pentaen-4-yl)pentanoylamino]ethoxy]ethoxy]ethyl]carbamate	1799385: WiDr from Article 10.1038/nchembio.2007.16: “Splicing factor SF3b as a target of the antitumor natural product pladienolide.”	ec50	0.0702	uM
[(2S,3S,6S,7R,10R)-7,10-dihydroxy-2-[(2E,4E,6S)-7-[(2R,3R)-3-[(2R,3S)-3-hydroxypentan-2-yl]oxiran-2-yl]-6-methylhepta-2,4-dien-2-yl]-3,7-dimethyl-12-oxo-oxacyclododec-6-yl] N-[2-[2-[2-[5-(2,2-difluoro-10,12-dimethyl-1-aza-3-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-3,5,7,9,11-pentaen-4-yl)pentanoylamino]ethoxy]ethoxy]ethyl]carbamate	507021: Inhibition of SAP130 in VEGF-stimulated human U251 cells by PLAP reporter gene assay	ic50	0.0784	uM
(4R,7R,8S,11S,12S)-4,7,8-trihydroxy-12-[(2E,4E,6S)-7-[(2R,3R)-3-[(2R,3S)-3-hydroxypentan-2-yl]oxiran-2-yl]-6-methylhepta-2,4-dien-2-yl]-7,11-dimethyl-oxacyclododecan-2-one	507021: Inhibition of SAP130 in VEGF-stimulated human U251 cells by PLAP reporter gene assay	ic50	0.3077	uM
(2E,4E,6R)-7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide	506784: Inhibition of SAP130 mediated cell growth in human WiDr cells	ic50	0.5776	uM
[(2S,3S,4E,6S,7R,10R)-7,10-dihydroxy-2-[(2E,4E,6S)-7-[(2R,3R)-3-[(2R,3S)-3-hydroxypentan-2-yl]oxiran-2-yl]-6-methylhepta-2,4-dien-2-yl]-3,7-dimethyl-12-oxo-1-oxacyclododec-4-en-6-yl] N-[(5S)-6-[2-[5-[(3aR,4R,6aS)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoyl-methylamino]ethyl-methylamino]-6-oxo-5-[[4-[3-(trifluoromethyl)diazirin-3-yl]benzoyl]amino]hexyl]carbamate	1799385: WiDr from Article 10.1038/nchembio.2007.16: “Splicing factor SF3b as a target of the antitumor natural product pladienolide.”	ec50	0.5950	uM
[(2S,3S,6S,7R,10R)-7,10-dihydroxy-2-[(2E,4E,6S)-7-[(2R,3R)-3-[(2R,3S)-3-hydroxypentan-2-yl]oxiran-2-yl]-6-methylhepta-2,4-dien-2-yl]-3,7-dimethyl-12-oxo-oxacyclododec-6-yl] N-[(5S)-6-[2-[5-[(3aR,4R,6aS)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoyl-methylamino]ethyl-methylamino]-6-oxo-5-[[4-[3-(trifluoromethyl)diazirin-3-yl]benzoyl]amino]hexyl]carbamate	507021: Inhibition of SAP130 in VEGF-stimulated human U251 cells by PLAP reporter gene assay	ic50	0.6448	uM
(4R,7R,8S,11S,12S)-4,7,8-trihydroxy-12-[(2E,4E,6R)-6-hydroxy-7-[(2R,3R)-3-[(2R,3S)-3-hydroxypentan-2-yl]oxiran-2-yl]-6-methylhepta-2,4-dien-2-yl]-7,11-dimethyl-oxacyclododecan-2-one	507021: Inhibition of SAP130 in VEGF-stimulated human U251 cells by PLAP reporter gene assay	ic50	2.1539	uM
(2R)-2-acetamido-3-[(2R,3S,4R)-3-hydroxy-2-[(1S)-1-hydroxy-2-methylpropyl]-4-methyl-5-oxopyrrolidine-2-carbonyl]sulfanylpropanoic acid	507021: Inhibition of SAP130 in VEGF-stimulated human U251 cells by PLAP reporter gene assay	ic50	3.4810	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149387: Binding affinity to human SF3B3 incubated for 45 mins by Kinobead based pull down assay	kd	6.0839	uM
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2179113: Binding affinity against SF3B3 (unknown origin) assessed as apparent dissociation constant incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	kd	7.7530	uM

CTD chemical–gene interactions

44 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases abundance, increases expression	3
Valproic Acid	affects expression, decreases expression, decreases methylation	3
cobaltous chloride	decreases expression	2
FR900359	increases phosphorylation	1
dicrotophos	increases expression	1
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases methylation	1
beta-lapachone	decreases expression	1
arsenite	affects binding, decreases reaction	1
perfluorooctanoic acid	decreases expression	1
butylidenephthalide	increases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, increases expression	1
di-n-butylphosphoric acid	affects expression	1
cylindrospermopsin	increases expression	1
bisphenol B	increases expression	1
abrine	increases expression	1
bisphenol AF	increases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	affects expression, increases abundance	1
Air Pollutants, Occupational	decreases expression	1
Arsenic	decreases expression, increases abundance	1
Atrazine	decreases expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Benztropine	decreases expression	1
Clozapine	affects cotreatment, decreases expression	1
Coumestrol	affects cotreatment, increases expression	1
Cuprizone	affects cotreatment, decreases expression	1
Dinitrochlorobenzene	affects binding	1
Doxorubicin	affects expression	1

ChEMBL screening assays

41 unique, capped per target: 41 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1226366	Binding	Binding affinity to SAP130 assessed as inhibition of radio labeled beta-globin pre-mRNA splicing after 1 hr by autoradiography	Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. — Nat Chem Biol

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer